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ABSTRACT Identifying the sequence polymorphisms underlying complex trait variation is a key goal of genetics research, since
knowing the precise causative molecular events allows insight into the pathways governing trait variation. Genetic analysis of complex
traits in model systems regularly starts by constructing QTL maps, but generally fails to identify causative sequence polymorphisms.
Previously we mapped a series of QTL contributing to resistance to nicotine in a Drosophila melanogaster multiparental mapping
resource and here use a battery of functional tests to resolve QTL to the molecular level. One large-effect QTL resided over a cluster of
UDP-glucuronosyltransferases, and quantitative complementation tests using deficiencies eliminating subsets of these detoxification
genes revealed allelic variation impacting resistance. RNAseq showed that Ugt86Dd had significantly higher expression in genotypes
that are more resistant to nicotine, and anterior midgut-specific RNA interference (RNAi) of this gene reduced resistance. We discov-
ered a segregating 22-bp frameshift deletion in Ugt86Dd, and accounting for the InDel during mapping largely eliminates the QTL,
implying the event explains the bulk of the effect of the mapped locus. CRISPR/Cas9 editing of a relatively resistant genotype to
generate lesions in Ugt86Dd that recapitulate the naturally occurring putative loss-of-function allele, leads to a large reduction in
resistance. Despite this major effect of the deletion, the allele appears to be very rare in wild-caught populations and likely explains only
a small fraction of the natural variation for the trait. Nonetheless, this putatively causative coding InDel can be a launchpad for future
mechanistic exploration of xenobiotic detoxification.
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A principal goal of research on the genetics of complextraits is to identify the precise sequence polymorphisms
responsible for phenotypic variation. This is either carried out
directly in natural populations or in laboratory mapping
panels derived from a sample of naturally derived chromo-
somes. The pursuit of causative alleles is open to criticism
(Rockman 2012), since with finite power it is necessarily the
case that experimentally identified causative variants repre-
sent a biased set of the complete collection of sites impacting
variation. Nonetheless, genomewide mapping studies have
provided important contributions to our understanding of
polygenic trait variation. Robust, replicable associations from
unbiased genomewide association studies (GWAS) have pro-
vided considerable insight into the pathways underlying dis-
ease risk (Hirschhorn 2009; Visscher et al. 2012). In addition,
the genes and molecular lesions contributing to an array of
crop domestication traits have been identified (Doebley et al.
2006; Gross and Olsen 2010), providing detail on the specific
molecular differences between modern crop plants and their
wild progenitors and an understanding of the nature of the
selection applied.
Inmodelorganisms, thehunt forcausativevariationcommonly
begins with linkage-based QTL mapping. Whether initiated with
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two parental strains (Lander and Botstein 1989) or, more
recently, with several founders (Kover et al. 2009; Churchill
et al. 2012; King et al. 2012b; Threadgill and Churchill 2012),
such mapping designs have tremendous power to find QTL,
and in some cases have led to the identification of specific
polymorphisms contributing to trait variation (e.g., Long et al.
2000; Deutschbauer and Davis 2005; Bendesky et al. 2011;
Cook et al. 2016; Linder et al. 2016). These variants facilitate
a deeper understanding of specific biomedically relevant
traits and collectively add to a fundamental appreciation of
complex trait variation and its maintenance in populations.
However, with the possible exception of yeast, where one can
test vast numbers of recombinants and minimize the statisti-
cal challenges associated with finding small-effect variants at
high resolution (Ehrenreich et al. 2010), it is quite clear that
linkage-based genomewide mapping for most complex traits
in most systems does not result in the identification of a
causative mutation.
The difficulty with moving from QTL to causative site is
compounded if traits are highly polygenic. Cornforth and Long
(2003) have shown by simulation that standard QTL mapping
approaches are unable to discriminate between a single QTL of
large effect and a series of very closely linked QTL that each
have independent effects. That such collections of adjacent
causative sites exist is amply demonstrated by fine mapping
studies that succeed in “fractioning” a single QTL intomultiple
causative loci (Pasyukova et al. 2000; Steinmetz et al. 2002;
Kroymann and Mitchell-Olds 2005), from elegant work show-
ing that multiple alleles combine to yield the major effect of
the Adh gene on alcohol dehydrogenase expression in flies
(Stam and Laurie 1996) and from recent work in multiparen-
tal mapping panels showing that QTL frequently appear to be
generated bymore than one segregating site (Baud et al. 2013;
King et al. 2014). Thus, to follow upQTLmapping and identify
functional allelic variation at the sequence level, additional
molecular and functional tests are typically required.
In Marriage et al. (2014) we described initial genetic dissec-
tion of nicotine resistance in D. melanogaster larvae, expanding
on studies that have identified genes and transcripts influencing
related nicotine resistance traits in flies (Passador-Gurgel et al.
2007; Li et al. 2012). Nicotine is an ecologically and biomedi-
cally interesting toxin for three reasons. It is produced by a
number of plants, most notably Nicotiana species, as a defense
against herbivory (Glendinning 2002; Steppuhn et al. 2004).
Nicotine was also commonly used as an agricultural pesticide
in the middle of the 20th century (Shepard 1951; Metcalf
1955), although it has since been supplanted by other insecti-
cides, including the chemically related neonicotinoids. Finally,
nicotine continues to be responsible for large numbers of human
deaths due to its addictive properties (Jha et al. 2013).
Marriage et al. (2014) used lines from the Drosophila Syn-
thetic Population Resource (DSPR), a set of inbred strains
derived from a multiparental, advanced generation inter-
cross (King et al. 2012b), and mapped a number of nicotine
resistance QTL. Two loci, Q1 on chromosome 2L and Q4 and
3R, had large effects on phenotype, explaining 8.5 and 50.3%
of the broad sense heritability, respectively. Both intervals
contained genes encoding detoxification enzymes, with Q1
encompassing two cytochrome P450 genes, and Q4, a set of
10 UDP-glucuronosyltransferase (or UGT) genes. These genes
are strong a priori candidates to contribute to xenobiotic re-
sistance, offering the possibility of identifying the underlying
causative alleles. Our goal here was to provide evidence that
one or more of these genes directly contributes to variation in
resistance, employing fine mapping, expression profiling, tis-
sue-specific RNAi, overexpression analyses, and CRISPR/Cas9
genome editing. Our data point to a single 22-bp InDel event in
a coding region of Ugt86Dd as a major factor contributing to
the previously mapped Q4 locus.
Materials and Methods
Larval nicotine resistance assay
We used the same assay described in Marriage et al. (2014),
except here we tested larvae in narrow polystyrene vials
rather than in plates. Briefly, flies were allowed to lay eggs
on a cornmeal–yeast–molasses medium containing 0.5% ac-
tivated charcoal, supplemented with a small amount of active
yeast paste to elicit egg laying. First instar larvae were col-
lected and placed either on no-drug media or on media con-
taining 0.18 ml/ml nicotine (N3876; Sigma). No-drug and
nicotine media were always prepared the day prior to larval
collection to minimize variation due to nicotine breakdown.
Replicate assay vials contained 30 first instar larvae in nearly
all cases (Supplemental Material, File S1), and the pheno-
type for each replicate vial is given as the fraction of larvae
that ultimately emerge as adults. For every genotype tested,
we set up several egg-laying vials, and the mean phenotype
is given as the average of multiple replicate assay vials.
All animals were reared and tested at 25 and 50% relative
humidity on a 12-hr-light/12-hr-dark cycle. Those test ani-
mals that were the result of crosses were generated by pairing
10 virgin females with four to five males over several repli-
cate vials. Prior to initiating such crosses, parental flies were
allowed to recover from CO2 anesthesia for 24 hr.
Chromosome substitution
Marriage et al. (2014) identified four autosomal QTL contrib-
uting to nicotine resistance and found that for each QTL,
recombinant inbred lines (RILs) harboring the A4 founder
allele were on average more resistant to nicotine than those
harboring the A3 allele (see figure 3 in Marriage et al. 2014).
To broadly examine the phenotypic effects of the A3 and A4
alleles, we generated the chromosome substitution lines A4/
A3; A4; A3 and A3/A4; A3; A4 (chromosomes are listed in the
order X/Y; 2; 3). We directly compared these substitution
genotypes to inbred strains A3 and A4 and carried out in-
tercrosses among strains to explore dominance. For each
genotype, we measured the phenotype using two replicate
no-drug vials to test for variation in overall viability and six
replicate nicotine-containing vials.
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To generate chromosome substitutions, the following
strains were obtained from the BloomingtonDrosophila Stock
Center (BDSC): the double-balancer strain 8316 (w1118;
wgSp-1/CyO; sensLy-1/TM6B, Tb1), the GFP-marked chromo-
some 2 balancer strain 5702 [w1; snaSco/Cyo, Gal4-Hsp70, up-
stream activating sequence (UAS)-GFP], and the GFP-marked
chromosome 3 balancer strain 5704 (w1; Sb1/TM3, Gal4-
Hsp70, UAS-GFP, y+ Ser1).
Quantitative complementation tests
To test for the effects of allelic variation between strains A3
(relatively susceptible to nicotine) andA4 (relatively resistant
tonicotine)atparticulargenomic regionsandat certaingenes,
we carried out quantitative complementation tests. Virgin
females from A3 and A4 were each crossed to males from a
seriesofmutation-containing lines, alongwith their co-isogenic
wild-type control lines, allowing the productionof four types of
F1 progeny per target mutation (A3/mutation, A3/control,
A4/mutation, and A4/control). Phenotypes were based on a
total of 2–8 replicate no-drug vials, and 8–18 replicate nicotine-
containing vials for each genotype. We employed the following
model for analysis: y=m+S+D+(S3D),whereS is the effect
of founder strain (A3 or A4), D is the effect of the mutation
(comparing either a deficiency or an insertion to wild type),
and S 3 D is the interaction. A significant S 3 D term indicates
a failure to complement (A3 and A4 functionally differ at the
locus under test).
Exelixis (Parks et al. 2004) and Bloomington Stock Center
(BSC) (Cook et al. 2012) deficiencies were obtained from the
BDSC, specifically 7497 [w1118; Df(2L)Exel6011/CyO],
7957 [w1118; Df(3R)Exel7306/TM6B, Tb1], 7958 [w1118;
Df(3R)Exel8152/TM6B, Tb1], and 26545 [w1118; Df(2L)
BSC693/SM6a], along with the co-isogenic control strain
6326 (w1118). We additionally obtained the DrosDel (Ryder
et al. 2004) deficiency 9083 [w1118; Df(3R)ED5506/TM6C,
cu1 Sb1] and its co-isogenic control 5905 (also w1118 but not
necessarily otherwise identical to 6326). All deficiencies are
maintained over balancers, and since we must discriminate
deficiency-containing and balancer chromosomes in larvae,
prior to use we substituted all native balancers with GFP-marked
versions derived from BDSC stocks 5702 and 5704 (see above).
Finally, we obtained several Minos-based insertional mutants
(Metaxakis et al. 2005), all of which were generated in the
5905 background: 23530 [w1118; Mi{ET1}4Cyp28d1MB03293],
23587 [w1118; Mi{ET1}Cyp28d2MB02776], 24834 [w1118;
Mi{ET1}Ugt86DjMB04890], and 27861 [w1118; Mi{ET1}
Ugt86DhMB11311].
RNAseq to identify nicotine resistance genes
Weselected six (12) lineswith relatively high (low) resistance
(File S2) from the set of DSPR pB2 RILs that were previously
scored for nicotine resistance (Marriage et al. 2014). Strains
were raised as described above: 30 first instar larvae from
each were placed on no-drug or nicotine-supplemented media
for 2 hr, after which larvae were flash frozen in liquid nitrogen
and stored at280. We isolated RNA from each sample using
TRIzol reagent (15596018; Thermo Fisher Scientific, Waltham,
MA) and purified using RNeasy columns (74104; Qiagen,
Valencia, CA). We then pooled equal amounts of total RNA
from each sample to generate four RNA pools (high/nicotine,
low/nicotine, high/no-drug, low/no-drug), generated an Illu-
mina TruSeq unstranded messenger RNA (mRNA) library
from each sample, and combined libraries to sequence over
a single HiSeq2500 lane and generate single-end 100-bp reads
[University of Kansas (KU) Genome Sequencing Core]. Reads
were quality trimmed using scythe (v0.991, github.com/
vsbuffalo/scythe) and sickle (v1.200, github.com/najoshi/
sickle), assembled to the D. melanogaster reference genome
[National Center for Biotechnology Information (NCBI) Build
5.3, ccb.jhu.edu/software/tophat/igenomes.shtml] using
TopHat v2.0.10 (Trapnell et al. 2009; Kim et al. 2013), and
significant expression differences between relevant pooled
samples were identified using Cufflinks v.2.2.1 (Trapnell
et al. 2010, 2013).
RNAi knockdown
We employed the binary Gal4-UAS RNAi system to knock
down expression of several candidate detoxification genes
ubiquitously and specifically in a number of tissues.We crossed
males from each Gal4 driver strain to females containing a
UAS-RNAi transgene, or to appropriate control females, and
assayed F1 Gal4-UAS-RNAi progeny. For each genotype we
phenotyped 3–5 replicate no-drug vials and 8–10 replicate
nicotine vials.
We obtained UAS-RNAi transgene-carrying stocks from the
ViennaDrosophila Resource Center (VDRC) (Dietzl et al. 2007).
The “GD” library strains harbor P-element-derived UAS trans-
genes, while the “KK” library strains harbor phiC31-based trans-
genes, where all transgenes reside at the same landing site.
Specifically, we use VDRC UAS-RNAi strains 6016 (GD, UAS-
RNAi-Ugt86Dd), 7870 (GD, UAS-RNAi-Cyp28d1), 7868 (GD,
UAS-RNAi-Cyp28d2), 100353 (KK,UAS-RNAi-Ugt86Dd), 102626
(KK, UAS-RNAi-Cyp28d2), and 110259 (KK, UAS-RNAi-
Cyp28d1). We directly compare genotypes containing these
transgenes to the appropriate control strains 60000 (GD
control strain) and 60100 (KK control strain). In addition,
we obtained the Transgenic RNAi Project (TRiP) (Perkins et al.
2015) strain 53892 (UAS-RNAi-Cyp28d1) and its co-isogenic
control (36304) from the BDSC.
WedroveRNAi in all cells and all timepoints usingAct5C-Gal4
[derived from BDSC 3954 (y1 w*; P{Act5C-GAL4}17bFO1/
TM6B, Tb1)], after first substituting the third chromosome
balancer in this strain for the GFP-marked version derived
from BDSC 5704 (see above). To drive RNAi in specific
groups of malpighian tubule cells, we employed a series
of strains obtained from Julian Dow and Shireen Davies
(University of Glasgow): c42-Gal4, c710-Gal4, c724-Gal4,
and uro-Gal4 (Rosay et al. 1997; Sozen et al. 1997; Terhzaz
et al. 2010). We obtained the anterior midgut Gal4 driver
1099 from Nicolas Buchon (flygut.epfl.ch). Finally, we
obtained a number of strains expressing Gal4 in various parts
of the gut from the BDSC, specifically strains 1967 [y1 w*;
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P{GawB}34B], 30828 [w*; P{GawB}Alp4c232], 30844 [w*;
P{GawB}c601c601], and 43656 [w*; P{Scr-GAL4.4}1-3].
Overexpression of Ugt86Dd
A gain-of-function analysis was performed for Ugt86Dd by
creating UAS-Ugt86Dd overexpression strains. We PCR am-
plified the gene from both A3 and A4, and simultaneously
added attB sites, using the primers 59-GGGGACAAGTTTGTACAA
AAAAGCAGGCTTACAACATGAGATTATTAACTGTGATCGCGA-39
and 59-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAATGT
TTCTTAAGCTTATCAG-39. Following themanufacturer’s protocol
(PCR Cloning System with Gateway Technology, 12535029;
Thermo Fisher Scientific) we cloned the PCR products into the
pDONR221 vector, creating entry clones via BP recombination
reactions. Clones were Sanger sequenced using M13 primers to
verify the sequence and direction of the insert. The destination
vector pUASg.attB was donated by Johannes Bischof (Bischof
et al. 2013) and used in combination with the LR reaction
(Gateway LR Clonase, 11791020; Thermo Fisher Scientific)
to generate both pUASg.Ugt86Dd-A3.attB and pUASg.
Ugt86Dd-A4.attB expression clones. Expression clones were
Sanger sequenced using primer hsp-GW-F (59-GCAACTACT
GAAATCTGCCAAG-39) to verify the direction of the insert. To
generate fly stocks we injected BDSC stock 24749 [y1 M{vas-
int.Dm}ZH-2A w*; M{3xP3-RFP.attP}ZH-86Fb] with the ex-
pression plasmids at 0.510-0.515mg/ml (BestGene, Chino
Hills, CA). We obtained one A3 transformant line (UAS-
Ugt86DdA3), and five A4 transformants [UAS-Ugt86DdA4(1)
to UAS-Ugt86DdA4(5)], that are each homozygous for the
transgene-containing chromosome 3. These strains were
utilized in conjunction with tissue-specific Gal4 drivers
(above) to explore the effects of Ugt86Dd overexpression.
For each genotype, we tested two to three replicate no-drug
vials and six replicate nicotine vials.
PCR genotyping assay for Ugt86Dd InDel variant
We identified a 22-bp InDel variant in a protein-coding region
of exon two of Ugt86Dd and developed a PCR assay to ge-
notype it. Primers 59-CGCTTTTGCTCAGCATTTTA-39 and
59-ATATGTGGCAGGTGAACGAA-39 amplify 219-bp and
197-bp products in the presence of the insertion and deletion
allele, respectively. PCR cycling conditions were 95 for
2 min, 35 cycles of 95 for 20 sec, 57 for 25 sec, and 72
for 30 sec, with a final 2-min extension at 72. Products were
sized on 2% gels run at low voltage for up to 2 hr.
QTL mapping
Marriage et al. (2014) detected a nicotine resistance QTL—
Q4—that encompasses Ugt86Dd using the DSPR. To test
whether the 22-bp InDel in Ugt86Dd might contribute to
the QTL effect, we first established the allelic status of the
DSPR founder lines via PCR, finding that founders A3, AB8,
B6, and B7 possess the deletion (Figure S1). Next, we employed
the estimated founder genotype probabilities for the DSPR RILs
(King et al. 2012b) to determine the InDel status of each RIL
(File S3).
Methods for QTL mapping in the DSPR are described in
King et al. (2012a,b). We employed the R (r-project.org)
packages DSPRqtl, DSPRqtlDataA, and DSPRqtlDataB for
mapping (FlyRILs.org), analyzed the pA and pB panels of
RILs separately, and—in addition to the InDel covariate—
included a covariate accounting for the subpopulation from
which the RIL was derived (pA1, pA2, pB1, and pB2). Note
that in the analyses conducted here, we only employed RILs
for which we had high confidence in the founder haplotype
at the Ugt86Dd gene, so sample sizes are marginally reduced
compared to those employed in Marriage et al. (2014), and
estimates of the QTL effect are slightly different than pre-
viously reported. To establish significance of mapped QTL,
we generated genomewide 5% significance thresholds via
1000 permutations (Churchill and Doerge 1994).
Testing the effect of the InDel variant in the Drosophila
Genetic Reference Panel
Our PCRassay revealed that seven strains from theDrosophila
Genetic Reference Panel (DGRP) (Mackay et al. 2012; Huang
et al. 2014) were homozygous for the deletion (BDSC nos.
25176, 25177, 25206, 28185, 28199, 28213, and 37525).
We also confirmed that the following seven strains were ho-
mozygous for the much more common insertion allele
(25174, 25200, 28160, 28197, 28226, 28239, and 28295).
We created a pair of populations, one fixed for the deletion
and one fixed for the insertion, by carrying out all possible
crosses between the seven founding strains (10 virgin females3
10males), collecting 10 F1 progeny of each sex from each cross,
and combining into a 1-gallon population bottle. Both popula-
tions were maintained for seven generations, at which point
we phenotyped each population using 20 replicate nicotine-
containing vials.
Ugt86Dd CRISPR/Cas9 editing
We used the CRISPR Optimal Target Finder (tools.flycrispr.
molbio.wisc.edu/targetFinder) to identify an appropriate
guide RNA (gRNA) target sequence within Ugt86Dd (Gratz
et al. 2014), specifically targeting the site of the 22-bp InDel.
The target sequence 59-TCACTACGAAGTCATTGTGGAGG-39
matches the sequence of A4 and was used to generate a gRNA
that leads to double-strand breaks within the insertion sequence
(Figure S1). We purchased the 59-phosphorylated sense and
antisense oligos 59- CTTCGTCACTACGAAGTCATTGTGG-39
and 59-AAACCCACAATGACTTCGTAGTGAC-39, annealed, and
followed the protocol from Gratz et al. (2013) to clone the
annealed oligos into the pU6–BbsI–chiRNA plasmid (Addgene,
Cambridge, MA; plasmid 45946). Transformants were verified
via Sanger sequencing.
Our goal was to compare the phenotypes of inbred strains
differing for wild-type andmutantUgt86Dd alleles in an other-
wise genetically identical background. Preliminary sequencing
revealed that chromosome 3 for the vasa-Cas9 BDSC strain
55821 [y1 M{vas-Cas9.RFP-}ZH-2A w1118] is not homozy-
gous. Thus, we used a series of standard fly crosses with bal-
ancers to substitute chromosome 3 from founder strain A4 into
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55821, creating a strain homozygous for vasa-Cas9 on the X
and A4 on chromosome 3 (the state of chromosome 2 is un-
known, but is likely heterozygous).
The gRNA plasmid was injected into 300 embryos from our
custom vasa-Cas9; ; A4 injection strain at 250 ng/ml (BestGene)
yielding 89 G0 progeny, 57 of which yielded progeny after being
individually crossed to one to two animals fromBDSC 5704 (see
above). Where possible we collected 10 F1 balanced progeny
from each G0 cross, and individually crossed to one to two an-
imals from BDSC 5704. For crosses containing a mutation (see
below), and for some that did not, we collected balanced F2
progeny of both sexes to establish stocks, removing the balancer
in subsequent generations to create strains carrying homozy-
gous third chromosomes. These strains can and do segregate
on the X and chromosome 2.
After each F1 cross produced eggs, we genotyped the F1
animal for the presence of a CRISPR/Cas9-induced mutation
using T7 endonuclease [New England Biolabs (NEB), Ipswich,
MA; M0302L]. Briefly, following single-fly DNA isolation
(Puregene Cell and Tissue Kit, 158388; Qiagen) we PCR am-
plified a region surrounding the gRNA target site using oligos
59-ACGCTTTTGCTCAGCATTTT-39 and 59-GGCTGGGGATAC
CATTTCTT-39 (95 for 2 min, 35 cycles of 95 for 20 sec, 57
for 25 sec, and 72 for 30 sec, with a final 2-min extension at
72). Subsequently 10 ml of PCR product was mixed with 7 ml
of molecular grade water and 2 ml of NEB buffer 2 (B7002S),
incubated at 95 for 5 min in a heat block, and allowed to
slowly cool to room temperature for 2 hr. We then added
1 ml of T7 endonuclease to each reaction, incubated at 37 for
15min, added 2 ml of 0.25 mM EDTA to stop the reaction, and
immediately loaded the entire reaction volume into a 1.5%
agarose gel.We also ranDNA fromA4 and from the F1 progeny
of A3 3 A4 crosses (which are heterozygous for the 22-bp
InDel) through this genotyping pipeline as negative and pos-
itive controls, respectively.
Editing led to 16 strains with homozygous third chromo-
somes carrying independent mutations in Ugt86Dd (File S4).
Simultaneously, we generated seven strains containing uned-
ited homozygous third chromosomes. Each of the 23 strains
created was phenotyped using 5–6 replicate no-drug and nico-
tine-containing vials. For two edited and one unedited geno-
type, we substituted the edited third chromosome into the A4
background, allowing a direct comparison of mutated and
wild-type versions of Ugt86Dd. Each of these strains—A4-
Ugt86DdDel1, A4-Ugt86DdDel11, and A4-Ugt86Ddwt (File S4)—
was tested directly as an inbred genotype, and as a heterozygote
following crosses to A4, using 10 replicate no-drug andnicotine-
containing vials.
Estimating the frequency of the InDel in nature
We can identify the two alleles at the short InDel directly from
reads resulting from next-generation sequencing of pooled
population samples ofD.melanogaster, thereby estimating allele
frequency. We retrieved raw FASTQ files from 13 wild-caught,
resequenced population samples (Bergland et al. 2014) via
the NCBI Sequence Read Archive (SRA) (BioProject accession
PRJNA256231), and used a Unix grep procedure to count the
number of raw reads containing the insertion and deletion
sequences.We ensured that instances of a sequence occurring
in both reads of a single paired-end fragment were counted
only once. The insertion-specific sequence was taken as
the central 20-bp (i.e., ATTGTGGAGGACATTCATCG) of the
22-bp InDel and its reverse complement. The deletion-
specific sequence was taken as the 10-bp either side of
the 22-bp InDel (i.e., GAACGAATTCACTTCGTAGT), and
its reverse complement. These query sequences match all
15 inbred DSPR founder strains (Figure S1).
Data availability
All rawphenotypesare presented inFileS1.RawRNAseq reads
are available from the NCBI SRA (accession no. SRP102254).
Results
Large, dominant effect of chromosome 3 on
nicotine resistance
Marriage et al. (2014) identified four autosomal QTL contrib-
uting to nicotine resistance in the pA DSPR population. Three
QTL on chromosome 2 (Q1–Q3) individually contributed
4.6–8.5% to the broad sense heritability of the trait, and one
QTL on chromosome 3 (Q4) contributed 50.3% to the herita-
bility. By estimating the effects associated with each founder
allele at each mapped QTL, it appeared that in all cases, car-
rying an A4 allele at the QTL led to greater resistance than
carrying an A3 allele. To confirm this, we tested various chro-
mosome substitution genotypes and observed that moving a
single third chromosome from A4 into an otherwise A3 back-
ground led to a marked increase in resistance compared to A3
(P , 1028, Figure 1). This implies that A3 and A4 do harbor
different alleles at functional variants within Q4, and that the
effect of the A4 chromosome is dominant.
In contrast to the large effect of chromosome 3, the com-
binedeffects of theXandchromosome2onnicotine resistance
are relatively small;Agenotypewith theA3third chromosome
homozygous in an otherwise A4 background is only margin-
ally more resistant than founder A3 (P=0.07, Figure 1). This
result confirms the smaller phenotype effects estimated at the
second chromosome QTL by Marriage et al. (2014).
Fine mapping nicotine resistance QTL
One strategy to fine map QTL is to employ quantitative comple-
mentation tests, either using deletions that remove tens to hun-
dredsof genes (Pasyukova et al.2000), or loss-of-functionmutant
alleles of plausible candidate genes (Long et al. 1996). We
crossed the A3 and A4 founders, which differ in nicotine resis-
tance, to a series of mutation-carrying strains and their corre-
sponding co-isogenic, mutation-free control strains, generating
four types of progeny (A3/mutation, A3/control, A4/mutation,
andA4/control).We thenused a statistical test that estimates the
effects of founder and mutation, and the interaction between
these factors. A significant interaction—a quantitative failure to
complement—implies the effects of founder alleles are different
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in the mutant and control backgrounds, and thus suggests
the founders segregate for functional variation at the tested
deficiency/gene.
We employed two small deficiencies that deleted over-
lapping regions of theQ1 region, one ofwhich eliminates both
of the P450 genes within the interval, Cyp28d1 and Cyp28d2,
and one of which deletes only Cyp28d1. Since the deletions
remove a total of 11–13 genes, including three additional
P450s not within the Q1 interval, we also employed a pair
of Minos insertions (Metaxakis et al. 2005) that insert within
coding exons of Cyp28d1 and Cyp28d2, likely disrupting gene
function. In all four cases, there was a highly significant
founder 3 mutant interaction (P , 1025, Figure S2) with
the difference between A3 and A4 being much greater in
the mutant background. Collectively these results imply that
both Cyp28d1 and Cyp28d2 show functional differences be-
tween A3 and A4 that confer effects on phenotype.
We carried out a similar experiment for the Q4 region,
testing three overlapping deficiencies that individually delete
11–19 genes, including variable numbers of the UGT genes
resident within Q4. All three deletions exhibit a significant
quantitative failure to complement (P , 1026, Figure S2).
Since Ugt86Dc is the only gene deleted by all three deletions,
a parsimonious explanation is that A3 and A4 have distinct
nicotine resistance alleles at this gene. However, Marriage
et al. (2014) showed that expression of this gene is reduced
in A4 compared to A3, which is not the pattern one might
expect under the assumption that Ugt86Dc leads to the
enhanced nicotine resistance of A4. Additionally, that
study provided evidence that the founder allelic effects at
Q4 do not fall into two groups, as would be expected if a
single causative gene was responsible for the QTL. Thus,
the different deletions may be uncovering variants in inde-
pendent genes that affect phenotype.
Finally, we tested a Minos element in a coding exon of
Ugt86Dj, and one that resides within the 39-UTR of one of the
two isoforms of Ugt86Dh. (Mutations in a known background
were available only for 2/10 of the UGT genes under Q4
when this experiment was conducted.) While we observed
a significant founder 3 mutant interaction for both genes
(Ugt86Dj, P, 0.001; Ugt86Dh, P, 0.01; Figure S2), in both
cases the difference between the A3 and A4 alleles was great-
est in the control background. These results suggest the ef-
fects are more likely due to epistasis than allelic failure to
complement (see Mackay 2001; Geiger-Thornsberry and
Mackay 2004), and do not provide strong evidence for the
role of functional variation at Ugt86Dh or Ugt86Dj in resis-
tance to nicotine.
Candidate nicotine resistance genes via RNAseq
Under the assumption that some fraction of complex trait
variation is regulatory in origin (Gibson andWeir 2005; Gilad
et al. 2008; Gusev et al. 2014; Torres et al. 2014; Albert and
Kruglyak 2015), we might expect to see changes in the ex-
pression of genes harboring causative loci. Marriage et al.
(2014) used RNAseq of whole, first instar larvae from A3
and A4 tested under no-drug and nicotine-exposure condi-
tions to attempt to resolve candidate genes. Here, we carried
out a similar study employing mixed pools of RNA from rel-
atively susceptible and relatively resistant pB DSPR RILs (File
S2).Many genes showed differential expression between sus-
ceptible and resistant genotypes and/or between treatments
(File S5), but those changes at loci within QTL intervals are of
principal interest.
Considering those 34 genes within Q1, only Cyp28d1 was
differentially expressed at a nominal 5% level, showing an
induction in expression on nicotine exposure in both suscep-
tible (P, 1024) and resistant animals (P = 0.001), confirm-
ing the results of Marriage et al. (2014). However, unlike our
previous study, we found no change in expression between
susceptible and resistant pB line pools that would indicate an
allelic difference between genotypes at this gene. Since Q1
was not identified in the pB DSPR panel, it is possible there is
no segregating variation that leads to expression variation
within this panel, althoughwe cannot discount the possibility
we failed to capture any such variation in the small number of
pB lines used for the current expression study (File S2).
At Q4, 5/10 UGT genes show a change in expression in at
least one contrast, with two genes showing a change between
susceptible and resistant genotypes; Ugt35b shows a slight
increase in expression in the resistant genotypes under
no-drug conditions (P , 0.05), while Ugt86Dd increases in
expression in resistant animals under both no-drug and nic-
otine conditions (P , 1024 and P = 0.001, respectively).
Marriage et al. (2014) found no effect at Ugt35b, but did
Figure 1 Effects of chromosome substitution on nicotine resistance.
Chromosomes derived from DSPR founder A3 are shown in white, and
those from A4 are shown in black. Nicotine resistance for each genotype
was tested across six replicate vials, and we performed all possible pair-
wise t-tests among genotypes. The three low resistance genotypes are
statistically indistinguishable, as are the five high resistance genotypes,
while all pairs of low and high resistance genotypes are significantly
different (P , 0.0001 in all cases). The viability of each genotype was
tested twice under no-drug conditions, and all genotypes showed a mean
viability of .0.9.
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observe expression differences between A3 and A4 in the
expression of Ugt86Dd. Since Q4 was identified in both the
pA and pB populations, the similar change in expression be-
tween susceptible and resistant genotypes derived from the
two panels implies Ugt86Dd is a strong candidate to harbor
functional genetic variation contributing to resistance.
Marriage et al. (2014) identified a small peak in the LOD
score profile in pB that encompasses the Cyp6g1 gene, a gene
shown to be associated with DDT (Daborn et al. 2002; Chung
et al. 2007; Schmidt et al. 2010) and nicotine resistance (Li
et al. 2012). However, we did not focus on the QTL in our
previous study, given the modest LOD score at the peak and
the relatively small number of pB RILs assayed. Here, we
found a dramatic increase in expression of Cyp6g1 between
susceptible and resistant pB genotypes in both no-drug and
nicotine conditions (P , 1024), providing some additional
support for the effect of this gene on nicotine resistance in
the DSPR.
Significant reduction in resistance following ubiquitous
gene knockdown
UnderQ1, the genesmost likely to harbor functional variation
impacting nicotine resistance are Cyp28d1 and Cyp28d2. Un-
der Q4, Ugt86Dd appears to be the strongest candidate based
on RNAseq data. We knocked down the expression of these
three genes using two to three different UAS transgenes per
gene. In comparison with co-isogenic control strains, we see a
robust reduction in resistance following knockdown of each
gene (Figure 2). Notably, gene knockdown had no effect on
viability under no-drug conditions; all strains showed pheno-
types above 0.93 on no-drug food (compare to Figure 2), and
there was no effect of gene knockdown under no-drug con-
ditions (P . 0.4 for all tests). Thus, the effects of reducing
expression of Cyp28d1, Cyp28d2, and Ugt86Dd appear to be
specific to nicotine resistance.
Knockdown of Cyp28d1 and Ugt86Dd in the midgut
reduces resistance
Data from FlyAtlas (Chintapalli et al. 2007; Robinson et al.
2013) indicates that Ugt86Dd expression is strongly enriched
in the adult midgut, and in the adult and third instar larval
malpighian tubules. In the same data set, Cyp28d1 shows
considerable among-tissue variation in expression, but has
highest expression in the adult midgut and larval fat body,
while Cyp28d2 is strongly enriched in the larval midgut. All
three genes additionally show variation in expression along
the length of the midgut in third instar larvae (Harrop et al.
2014) and variation among adult midgut cell types (Dutta
et al. 2015). These data show where the genes are expressed
at high levels, but do not directly establish where they might
act to metabolize nicotine. To help achieve this, we employed
RNAi with a series of tissue-specific Gal4 drivers. Using two
drivers that express Gal4 in the anterior region of the midgut,
we saw that RNAi of Cyp28d1 (in 5/6 cases) and Ugt86Dd (in
4/4 cases), but not Cyp28d2 (in 0/4 cases), led to a signifi-
cant reduction in resistance (Table 1). In contrast, a driver
expressing Gal4 in the posterior region of the midgut showed
no effect of any target gene (Table 1). These data imply that
the anterior midgut is an important site of nicotine metabo-
lism and is impacted by the action of the products of Cyp28d1
and Ugt86Dd, genes showing expression variation between
resistant and susceptible genotypes (above and Marriage
et al. 2014). The lack of any apparent effect of Cyp28d2 in
the midgut (Table 1), in contrast to the effect observed fol-
lowing ubiquitous knockdown of the gene (Figure 2) might
imply that Cyp28d2 is required in a different, and untested
tissue. Alternatively, the ubiquitous knockdown effect de-
scribed above may be a false positive, which is known to
occur at low rates in RNAi screens (e.g., Mummery-Widmer
et al. 2009; Schnorrer et al. 2010).
Malpighian tubule knockdown of target detoxification
genes enhances resistance
The malpighian tubules are an important site of xenobiotic
metabolism in insects (Dow and Davies 2006; Yang et al.
2007), and we tested multiple Gal4 drivers that broadly
express in the malpighian tubules, and also those that target
specific cell types within the organ. RNAi against three
genes (Cyp28d1, Cyp28d2, and Ugt86Dd) using drivers
expressing Gal4 broadly in the malpighian tubules, and in
one case additionally in the hindgut and ureter, revealed no
major changes in resistance (Table 2). However, in nearly all
cases, knockdown of these genes in either principal or stel-
late cells of the malpighian tubule led to a significant in-
crease in resistance in comparison with control genotypes
(Table 2). We note that under no-drug conditions, all geno-
types associated with these malpighian tubule cell-specific
Figure 2 Effect of ubiquitous gene knockdown on nicotine resistance.
We employed the Gal4-UAS-RNAi system to knock down the expression
of three genes in all cells and at all timepoints via Act5C-Gal4. Each
genotype was tested across eight replicate vials (raw data shown in gray
symbols), and the mean (61 SD) phenotype of each is shown with colored
symbols/lines. Within each RNAi system (VDRC-GD, VDRC-KK, and TRiP) we
tested the effect of each gene knockdown against its co-isogenic control using
t-tests, and significance is highlighted by asterisks (* P , 0.05, ** P , 0.01,
*** P , 0.001). All ubiquitous RNAi knockdowns reduce nicotine resistance.
Note that the viability of each genotype was tested four to five times in
no-drug conditions, and all genotypes showed a mean viability of .0.93.
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tests show viabilities.0.93, implying the relative increase in
resistance on gene knockdown is in response to the nicotine
treatment.
This result—heightened resistance to a drug after knock-
ing down expression of known detoxification genes in cell
types known to be involved in xenobiotic metabolism—is
counterintuitive. Indeed, RNAi knockdown of the P450 gene
Cyp6g1 in principal cells robustly leads to a reduction in DDT
resistance (Yang et al. 2007). We speculate that the presence
of nicotine or its byproducts, coupled with a reduction in
expression of key nicotine metabolizers in the malpighian
tubule principal/stellate cells, leads to the production of ad-
ditional detoxification enzymes, possibly in other tissues, that
enhance resistance. Analyses of gene expression in the mal-
pighian tubules and other gut tissues of these knockdown
genotypes may provide insight into this observation.
Overexpression of functional Ugt86Dd enhances
nicotine resistance
Using the Ugt86Dd sequence from the relatively susceptible
A3 founder and the relatively resistant A4 founder, we made
UAS-Ugt86Dd strains, allowing ectopic overexpression of the
Ugt86Dd gene product. In the course of verifying clones prior
to plasmid injection, we noticed that exon 2 of the A3 allele
contained a 22-bp deletion relative to A4, leading to a frame-
shift and a premature stop codon, reducing the length of the
predicted protein product from 517 to 206 amino acids. PCR
and sequencing of the original founders revealed that the A3
and A4 strains differ at this variant.
Ubiquitous overexpression of UAS-Ugt86DdA4 via Act5C-
Gal4 did not yield viable Gal4-UAS offspring under no-drug
conditions, while similar overexpression of UAS-Ugt86DdA3
did yield Gal4-UAS progeny. These observations imply that
ubiquitous overexpression of full-length Ugt86Dd is poison-
ous to cells and confirms that A3 carries a nonfunctional
Ugt86Dd allele.
In order to test the effect of Ugt86Dd overexpression on
nicotine resistance we used a series of drivers expressing Gal4
in various regions of the gut and compared a single line con-
taining the UAS-Ugt86DdA3 transgene to five strains contain-
ing the same UAS-Ugt86DdA4 transgene. Figure 3 shows that
for every Gal4 driver, overexpression of UAS-Ugt86DdA4
(containing the insertion allele of Ugt86Dd) leads to higher
nicotine resistance than overexpression of UAS-Ugt86DdA3
(containing the deletion). These data suggest that the InDel
variant segregating between strains A3 and A4 may be re-
sponsible for some of the difference in nicotine resistance
exhibited by these strains. We note that while all six strains
tested are homozygous for the same third chromosome har-
boring the transgene landing site, theymay be variable on the
second and X chromosomes due to postinjection crossing
against balancers. Thus, it is conceivable that some of the
variation observed between the A3 and A4 transgenes is
due to differences in genetic background.
This overexpression experiment may not say anything
about the natural site of Ugt86Dd-based nicotine detoxifica-
tion, since we are ectopically expressing the gene at high
levels in tissues where it may normally be expressed at more
modest levels under its native promoter.
The Ugt86Dd InDel variant is associated with
nicotine resistance
Four of the DSPR founder strains (A3, AB8, B6, and B7)
possess the 22-bp deletion allele at Ugt86Dd (Figure S1). At
the Q4 QTL identified by Marriage et al. (2014) these four
founders have the lowest strain effects, suggesting the InDel
may have a functional role in resistance. Furthermore, mean
phenotypes of RILs carrying the insertion and deletion alleles
are highly significantly different for both the pA and pB pop-
ulations (t-test, P, 10215; File S3), with the mean resistance
of the deletion-containing RILs being 37% (pA) and 27%
(pB) less than that of the insertion-containing RILs.
We employed InDel status as an additional covariate in the
DSPR QTL mapping analysis and observed a substantial re-
duction in LOD score at the site of the Q4 locus (Figure 4),
eliminating any above-threshold peak in pB and leaving a
Table 1 Effect of midgut-specific gene knockdown on nicotine resistance
RNAi system UAS genotype
Mean nicotine resistance (61 SD)
Anterior midgut Gal4 (1099) Anterior midgut Gal4 (43656) Posterior midgut Gal4 (1967)
VDRC-GD Control (GD) 0.95 6 0.032 0.96 6 0.032 0.83 6 0.096
Cyp28d1 0.90 6 0.064* 0.92 6 0.039* 0.88 6 0.047ns
Cyp28d2 0.92 6 0.050ns 0.96 6 0.033ns 0.89 6 0.072ns
Ugt86Dd 0.90 6 0.070* 0.90 6 0.025*** 0.89 6 0.093ns
VDRC-KK Control (KK) 0.84 6 0.063 0.95 6 0.032 0.73 6 0.099
Cyp28d1 0.77 6 0.086* 0.88 6 0.050** 0.75 6 0.085ns
Cyp28d2 0.84 6 0.052ns 0.93 6 0.078ns 0.76 6 0.124ns
Ugt86Dd 0.77 6 0.058* 0.89 6 0.053** 0.75 6 0.083ns
TRiP Control (TRiP) 0.93 6 0.060 0.94 6 0.050 0.70 6 0.069
Cyp28d1 0.83 6 0.073** 0.91 6 0.054ns 0.78 6 0.079ns
The Gal4-UAS-RNAi system was used to knock down expression of three genes in the midgut. The phenotype of each genotype was tested over 7–10 (mean = 9.5) replicate
vials. Each gene knockdown was tested against the relevant co-isogenic control using a t-test (ns P $ 0.05, * P , 0.05, ** P , 0.01, *** P , 0.001). The viability of each
genotype was tested two to five times in no-drug conditions. These genotype means averaged 0.92, 24/30 of the genotypes have greater no-drug viability than nicotine
viability, and for the other six genotypes no-drug viability was at most 4% less than that on nicotine food. These observations suggest the effects of these tissue-specific gene
knockdowns are not a result of general defects in viability.
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much more modest effect at the locus in pA; in the standard
analysis, Q4 contributes 46.5% to the variation among pA
lines, whereas the above-threshold peak at the same location
after accounting for the InDel contributes 5.3% to the varia-
tion. These data imply that the InDel variant alone, or one or
a collection of variants in linkage disequilibrium (LD) with
this variant, are responsible for a large fraction of the nicotine
resistance variation in the DSPR and may completely, or
nearly completely, explain the major-effect QTL mapped by
Marriage et al. (2014).
Toattempttovalidatetheeffectof theInDelvariantonnicotine
resistance, we exploited the DGRP, a collection of 200 inbred,
resequenced strains of D. melanogaster (Mackay et al. 2012;
Huang et al. 2014). Seven of the DGRP strains were found to
harbor the same 22-bp deletion allele as found in the DSPR.
We intercrossed these lines for seven generations to gener-
ate a population fixed for the deletion allele, but otherwise
outbred, and generated a similar population from seven
random DGRP strains carrying the insertion allele. Compar-
ing these populations revealed a small, yet significant re-
duction in resistance in the deletion population (insertion
population mean = 0.94, deletion population mean = 0.89,
t-test, P= 0.011). While this result does tend to validate our
work in the DSPR, any effect of the Ugt86Dd InDel variant is
apparently much smaller in the DGRP.
CRISPR/Cas9-derived deletion mutations at Ugt86Dd in
A4 reduce resistance
The effect of the deletion allele in founder A3 is to generate a
premature stop codon in Ugt86Dd. To directly test the effect
of premature stop-encoding mutations in this gene, we gen-
erated a series of deletion alleles via CRISPR/Cas9 editing.
We constructed a custom injection strain containing an
X-linked vasa-Cas9 transgene and an A4-derived third chro-
mosome and employed a gRNA that generates double-strand
breaks at the site of InDel (Figure S1). We generated a series
of 16 independent mutations (File S4), 13 of which lead to
premature stop codons, and constructed strains carrying ho-
mozygous edited third chromosomes for all 16. Simulta-
neously, we made seven strains with homozygous unedited
third chromosomes from genotypes that were passed through
the CRISPR/Cas9 process (injection, balancing, and so on).
Our rationale for keeping such genotypes was that during the
creation of our injection strain, and while establishing homo-
zygous edited chromosomes, we employed several genera-
tions of crossing with balancers. Since movement of genetic
material via gene conversion from a balancer to the nonba-
lancer homolog has been inferred (Blumenstiel et al. 2009),
such unedited genotypes provided valuable controls for the
effects of induced mutations. All 23 strains were tested in
multiple replicates for viability under no-drug and nicotine
conditions, and while we observed no difference between the
sets of unedited and edited genotypes in the absence of nic-
otine (P = 0.2), we saw a large decrease in resistance due to
editing (P , 10215, Table S1).
The fact that the three lesions that result in amino acid
changes, but do not introduce a premature stop codon, still
each lead to a strong reduction in nicotine resistance may
suggest that the region of the protein targeted for mutation is
critical to the function of Ugt86Dd.
For two deletion alleles—a 1-bp and an 11-bp deletion—
that both lead to premature stop codons, along with one un-
edited allele, we used standard fly genetics to put the third
chromosome (originally derived from A4) into a complete
A4 background, generating strains A4-Ugt86DdDel1, A4-
Ugt86DdDel11, and A4-Ugt86Ddwt. All three have marginally
reduced viability under no-drug conditions compared to the
original A4 founder strain (P = 0.03–0.06), perhaps indica-
tive of novel mutations relative to the A4 progenitor line, or
slight changes in sequence due to gene conversion from bal-
ancers during stock construction. Nonetheless, Figure 5 shows
that both of the deletion-carrying stocks A4-Ugt86DdDel1 and
A4-Ugt86DdDel11 have significantly reduced nicotine resistance
in comparison with A4-Ugt86Ddwt (P , 1024 and P , 0.001,
respectively). The induced mutations appear to behave reces-
sively, since measuring the phenotype of their heterozygous
progeny after crossing to A4 recapitulates the A4 homozygous
phenotype (Figure 5).
Thedifference in nicotine resistance between strainsA3 and
A4 is 0.69–0.77 (Figure 1 and Figure 5), while A4-Ugt86DdDel1
Table 2 Effect of malpighian tubule RNAi on nicotine resistance
Gal4 driver
Mean nicotine resistance (61 SD)
Control (GD) UAS-Cyp28d1 UAS-Cyp28d2 UAS-Ugt86Dd
30844 0.93 (0.060) 0.94 (0.046)ns 0.86 (0.055)* 0.89 (0.083)ns
30828 0.90 (0.060) 0.92 (0.061)ns 0.88 (0.059)ns 0.90 (0.079)ns
c42 0.85 (0.074) 0.92 (0.039)* 0.91 (0.066)ns 0.94 (0.051)**
uro 0.69 (0.211) 0.94 (0.063)** 0.91 (0.045)** 0.95 (0.023)**
c710 0.74 (0.079) 0.91 (0.068)*** 0.88 (0.061)*** 0.92 (0.061)***
c724 0.77 (0.083) 0.89 (0.072)** 0.81 (0.077)ns 0.93 (0.054)***
We knocked down expression of three genes, using UAS constructs from the VDRC-GD collection, with six different Gal4 drivers. The 30844 driver expresses Gal4 in the
hindgut, ureter, and malpighian tubules, 30828 expresses Gal4 in the malpighian tubules, c42-Gal4 and uro-Gal4 are specific to the principal cells of the malpighian tubules,
and c710-Gal4 and c724-Gal4 are specific to tubule stellate cells. The phenotype of each genotype was tested across 10 replicate vials, and each gene knockdown was
compared to the relevant co-isogenic control using a t-test (ns P $ 0.05, * P , 0.05, ** P , 0.01, *** P , 0.001). The viability of each genotype was also tested two to five
times under no-drug conditions. The lowest genotype mean under no-drug conditions was 0.88, and the average genotype mean was 0.95. Notably, the mean phenotypes
under no-drug conditions for the non-RNAi, control genotypes were 0.91–0.98, implying that the marked reduction in viability for some of these genotypes on nicotine-
supplemented media is not due to general viability defects.
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and A4-Ugt86DdDel11 differ from A4-Ugt86Ddwt by 0.28 and
0.19, respectively. This suggests that 25–41% of the difference
between founders A3 and A4 could be due to functional var-
iation at Ugt86Dd, with the most likely variant conferring this
effect being the naturally segregating 22-bp InDel. Since the
difference between the mean phenotype of RILs carrying the
A3 andA4 alleles at theQ4 locus is 0.37 (Marriage et al. 2014),
our gene editing data again imply that Ugt86Dd, and likely the
InDel variant that results in an allele containing a similar pre-
mature stop codon to the edited mutations, confers the bulk of
the effect observed at this QTL.
Discussion
Variation at Cyp28d1 may underlie nicotine resistance
Quantitative complementation tests suggest that functional
allelic variation is present at Cyp28d1 (Figure S2). Previous
RNAseq data (Marriage et al. 2014) suggest gene expression
is higher in the more resistant A4 line than in the more
susceptible A3 line, and both ubiquitous and anterior mid-
gut-specific RNAi of Cyp28d1 led to a reduction in nicotine
resistance (Figure 2 and Table 1). These results strongly
implicate variation at Cyp28d1 in the genetic control of nic-
otine resistance. Data from Chakraborty et al. (2017), who
have generated an assembly of DSPR founder A4 based on
long-read sequencing data, give some indication that varia-
tion in Cyp28d1 copy number may be causative; in contrast
to the D. melanogaster reference strain, founder A4 pos-
sesses two copies of Cyp28d1. The relatively high expression
of Cyp28d1 in A4 (Marriage et al. 2014) supports the idea of
a positive correlation between copy number and gene expres-
sion, which could in turn lead to enhanced resistance. Such pos-
itive associations between P450 copy number and xenobiotic
resistance have been reported previously (Wondji et al. 2009;
Schmidt et al. 2010). Nonetheless, the relationship between copy
number and expression level is not straightforward (Zhou et al.
2011; Schrider et al. 2016), andwhile the presence of two copies
ofCyp28d1 in a strain resistant tonicotine is suggestive, establish-
ing a direct effect requires functional validation.
Evidence that Cyp28d2 also contributes to nicotine resis-
tance, and segregates for causative variation generating the
Q1 locus, is marginally more mixed. A quantitative comple-
mentation test using an insertional mutant implies the gene
harbors a functional difference between strains A3 and A4
(Figure S2), strain A4 exhibits higher expression than A3
(Marriage et al. 2014), and ubiquitous knockdown of Cyp28d2
decreases resistance (Figure 2). However, knockdown of the
gene in the midgut had no detectable effect (Table 1). It is
possible that we did not knock down Cyp28d2 in the tissue in
which it would normally act on nicotine, and failed to identify
an effect. Employing an expanded catalog of Gal4 drivers
(Buchon et al. 2013)may uncover the tissue inwhich Cyp28d2
is active against nicotine. Given our data, either Cyp28d1 or
Cyp28d2, or indeed both genes, may contribute to the effect
observed at the Q1 locus originally mapped by Marriage et al.
(2014). Additional fine mapping in natural populations, where
both genes appear to segregate for copy number variants
(CNVs) (Good et al. 2014), may be profitable and allow func-
tional effects associated with the two genes to be separated.
Ugt86Dd explains a large fraction of the variation for
nicotine resistance in the DSPR
Deficiency quantitative complementation tests suggest that
the set of UGT genes under Q4 may harbor functional allelic
variation affecting nicotine resistance, although these tests do
Figure 3 Effect of tissue-specific overexpression of Ugt86Dd alleles. We
overexpressed Ugt86Dd derived from strains A3 (which contains a 22-bp
out-of-frame coding deletion) and A4 (which carries an allele making a
full-length gene product) using seven tissue-specific Gal4 drivers. We
had access to a single UAS-Ugt86DdA3 transgene line and five UAS-
Ugt86DdA4 transgene lines and tested each line over six replicate nicotine
vials (gray open symbols). We present the mean (61 SD) phenotype of
each genotype in colored symbols and compared the genotype means for
each Gal4 driver using t-tests (* P, 0.05, ** P, 0.01, *** P, 0.001). In
every case, the A4 transgene leads to higher nicotine resistance. Notably,
we additionally tested all genotypes across two to three no-drug vials,
and the A3 transgene showed viabilities of 0.84–0.96. This indicates that
the reductions in viability under nicotine conditions are nicotine specific
and likely not due to expression of the UAS-Ugt86DdA3 transgene being
generally deleterious.
Figure 4 An InDel variant in Ugt86Dd explains variation at a nicotine
resistance QTL. Each plot shows the LOD curve along chromosome 3,
with genetic distance along the x-axis, in the pA (left) and pB (right) DSPR
populations. In blue, using a standard mapping analysis in the DSPR, one
sees evidence for the major-effect QTL Q4. In red, using a similar analysis
but now including a covariate accounting for the InDel status of each
phenotyped RIL, one sees a peak in pA with a LOD score just surviving the
threshold, and no peak in pB. These data suggest the InDel variant con-
tributes to the effect observed at Q4.
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not directly implicate Ugt86Dd (Figure S2). RNAseq, both
from the present study and Marriage et al. (2014), suggest
Ugt86Dd is more highly expressed in more resistant geno-
types. Knocking down the gene ubiquitously (Figure 2) and
in the anterior midgut (Table 1) leads to reduced resistance,
while overexpression of full-length Ugt86Dd enhances resis-
tance compared to overexpression of a putatively null allele
(Figure 3). All this evidence strongly implicates Ugt86Dd as a
major source of genetic variation contributing to nicotine
resistance.
The segregating 22-bp coding InDel is a compelling can-
didate for the actual causative site underlying much of this
variation. By accounting for the polymorphism during QTL
mapping the effect of the Q4 interval is markedly reduced
(Figure 4), and comparison of DGRP-derived populations
fixed for alternate alleles at the InDel suggest the deletion
is associatedwith reduced resistance. Finally, while we do not
specifically generate the 22-bp deletion in the A4 background,
our creation and testing of other deletions at a similar location
in the Ugt86Dd gene, which similarly lead to premature stop
codons, provides strong evidence that the InDel is functional,
and directly leads to an effect on nicotine resistance (Figure 5).
Several pieces of evidence suggest that additional poly-
morphisms also contribute to the effect observed at the Q4
locus. First, the strain effects at the mapped QTL do not fall
into two categories, as would be expected if a biallelic caus-
ative polymorphism was solely responsible for the QTL effect
(Marriage et al. 2014). Second, a quantitative complementa-
tion test using a deficiency that eliminates several UGT genes,
but leaves Ugt86Dd intact, showed a significant failure to
complement, implying other genes in the QTL region may
segregate for functional variation (Figure S2). Third, after
accounting for the InDel, QTL mapping in the pA population
still yields a modest-effect QTL at the Q4 interval, suggesting
factors not in perfect LD with the InDel in the DSPR are
additionally involved. Such variants could impact other
genes in the Q4 interval, but potentially might affect the
regulation and/or coding sequence of Ugt86Dd in alleles
derived from founders other than A3 and A4. Finally, the
difference between the strain effects of A4 (which carries
the insertion at Ugt86Dd) and A3 (which carries the dele-
tion) at QTL Q4 is larger than the phenotypic difference
between wild-type and edited mutant Ugt86Dd alleles in
the same A4 background. Assuming the effects of the natu-
rally occurring deletion at Ugt86Dd in A3 and the CRISPR/
Cas9-induced deletion in A4 are the same, this observation
is most likely due to variants in other genes in the QTL
interval.
One factor that could contribute to the Q4 QTL in addition
to Ugt86Dd is a CNV at Ugt86Dh (Chakraborty et al. 2017),
where founder A4 harbors two copies of this gene relative to
theD.melanogaster reference genome (althoughwe do not yet
know the status of this gene in other DSPR founders.) Notably
two copies ofUgt86Dh increase expression (Chakraborty et al.
2017), implying the CNV may have some functional effect,
and the gene is deleted in the one deficiency that does not
eliminate Ugt86Dd (Figure S2). Given the circumstantial
evidence associated with Ugt86Dh, it is a strong candidate
for additional follow-up functional characterization.
Effect of the segregating InDel at Ugt86Dd
Given the apparent large effect of the InDel in the DSPR, and
specifically the effect of introducingapremature stop-encoding
lesion into A4, we anticipated the effect of the deletion would
routinely be large. However, comparison of DGRP-derived
populationsfixed for alternate alleles at the InDel showed only
a modest effect of the variant. Our design assumes we can
estimate the effect of each allele at the InDel averaged over a
similarly randomized genetic background.However, due to the
paucityofDGRPlinespossessingthedeletion, it is likely that the
insertion and deletion populations show many other fixed
differences along the genome, some of which could lead to
underestimating any true effect of the variant.
Outside of this technical challenge, one possibility for the
very different effect estimates of the InDel inDSPR- andDGRP-
derived populations is the different genetic background of the
twopanels. TheDSPR isderived fromaworldwide collectionof
P-element-free strains that have been present in laboratories
for decades (King et al. 2012b), while the DGRP is a set of
strains relatively recently collected from North Carolina
(Mackay et al. 2012). One observation suggesting these
populations may have different genetic architectures for
nicotine resistance comes from work by Passador-Gurgel
et al. (2007). This study demonstrated that flies derived
from North Carolina are commonly more nicotine resistant
Figure 5 Phenotypes of background-controlled Ugt86Dd CRISPR/Cas9-
derived mutations. We made a pair of Ugt86Dd mutations homozygous
in the A4 background. Del1 introduces a 1-bp mutation, while Del11
introduces an 11-bp mutation, each leading to a different stop codon
mutation (File S4). In addition, we passed an unedited allele (wt) through
an identical crossing scheme, which should be identical to the pure A4
strain. We tested 10 replicate vials of each of the genotypes in the plot for
both no-drug (gray bars) and nicotine (yellow bars) treatments and present
the mean (61 SD) viability across replicate vials. The two homozygous
mutant strains (Del1/Del1 and Del11/Del11) have significantly lower nico-
tine resistance (t-test, P , 1025) in comparison to the parental A4 geno-
type and the unedited control strain (wt/wt). Since the unedited control
strain has slightly, but significantly reduced resistance in comparison to A4
(P, 0.01), the crossing scheme used to establish the homozygous CRISPR/
Cas9-derived genotypes may have resulted in some additional changes in
addition to the target mutation.
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than flies derived from California. Indeed, using our assay we
find that average nicotine resistance in our DGRP-derived out-
bred populations is higher than all but three of the 1274 DSPR
RILs assayed by Marriage et al. (2014). While we can only
speculate that there is an interaction between the InDel and
variation at other functional variants, we know that epistasis
contributes significantly to phenotypic variation (Monnahan
and Kelly 2015; Forsberg et al. 2017), and that large-effect
mutations moved into a varied set of genetic backgrounds re-
sult in a spectrum of phenotypic expression (Chandler et al.
2013; Chari and Dworkin 2013; He et al. 2014; Sittig et al.
2016). Thus, there is the potential for genetic background to
influence the phenotypic expression of the Ugt86Dd variant.
A way to both establish the causative effect of the 22-bp
Ugt86Dd InDel in the DSPR, as well as to estimate any back-
ground-specific expression of the variant alleles in the DGRP
(and other populations), is to use CRISPR/Cas9 to precisely
introduce the deletion into strains carrying a wild-type
Ugt86Dd sequence, and similarly “repair” the allele in strains
carrying the deletion (see Gratz et al. 2013). Such reagents
would additionally facilitate future work on the mechanisms
underlying nicotine detoxification by Ugt86Dd, for instance,
by examining the products of nicotine metabolism, and allow
tests of the effect of the Ugt86Dd gene in the detoxification of
other xenobiotics, perhaps neonicotinoid insecticides.
Ugt86Dd deletion is rare and recessive
Among the 15 DSPR founder strains, the 22-bp deletion allele
at Ugt86Dd is fairly common (4/15 or 27%). To assess its fre-
quency in wild-caught population samples, we searched for
next-generation sequencing reads that perfectly match the de-
letion and insertion alleles at the variant in a series of pooled
resequencing data sets derived from a number of United States
populations (see Materials and Methods and Bergland et al.
2014). Averaging over these samples we roughly estimate the
frequency of the deletion in nature at2% (Table S2), although
there is fairly large sample-to-sample variation around this value
(0–11%) that could represent real biological, among-population
variation, or simply be a result of sampling (of both individuals
and sequencing reads.)
The deletion allele leads to a premature stop, likely ablat-
ing gene function, and purifying selection may perhaps ex-
plain the low frequency of the allele in nature. Huang et al.
(2014) identified variants in the set of 200 DGRP fly strains
that potentially generate a damaged protein, and found that
such variants are typically less frequent than other sites (e.g.,
nonsynonymous variants). Similarly, studies in humans have
shown that rare, protein-coding polymorphisms are enriched
for putatively damaging events (MacArthur et al. 2012; Nelson
et al. 2012; Tennessen et al. 2012). Since theUgt86Dd deletion
appears to be recessive (Figure 5), under the assumption there
is some cost to an organism in nature carrying the deletion in
homozygous form, this might explain why its frequency in
nature is not even lower.
It is not clearwhy the deletion allele is fairly common in the
DSPR founders. The founderswere collected in the 1950s and
1960s from a number of different countries (King et al.
2012b), prior to the P-element sweep throughD.melanogaster,
and conceivably populations were enriched for the deletion
during this period. However, given the small number of foun-
ders, and their arbitrary sampling from stock centers many
generations after their original derivation from nature (King
et al. 2012b), a deletion frequency of 4/15 may not reflect the
actualworldwide population frequency of the allele at the time
of collection. It is tempting to speculate that the frequency of
the Ugt86Dd deletion allele has been modulated by the use
of nicotine as an insecticide. Nicotine was in common use as
a pesticide after World War II (Shepard 1951; Metcalf
1955), but is no longer used in this way in the United States
(Environmental Protection Agency 2009), having been sup-
planted by other insecticides, many of which are nicotine
derivatives (Goulson 2013). However, it is known that indi-
vidual UGT genes can act on a range of substrates (Tukey
and Strassburg 2000), so any selection acting on Ugt86Dd
could be due to one or more unknown compounds to which
flies can be exposed in nature.
Despite the large effect of the InDel in theDSPR, replicated
by our CRISPR/Cas9 editing, the recessive nature of the de-
letion allele and its low frequency in nature likely means the
InDel explains only a very small fraction of the variation in
nicotine resistance in a natural, outbred diploid population.
Using the formula appropriate for a completely recessive
variant, Va = 8pq3a2 (Falconer and Mackay 1996), estimating
the frequency (q) of the deletion allele at 2%, taking the effect
of the deletion from the difference between the background
matched wild-type Ugt86Dd genotype and the CRISPR-
derived lesions (0.19–0.28), and assuming the phenotypic
variance among DSPR line means (Marriage et al. 2014) is
representative of that in a natural population, the InDel
explains ,0.01% of the phenotypic variation for the trait.
This estimate is lower still if the difference between homo-
zygous insertion- and deletion-carrying genotypes are more
in line with the values observed for the DGRP populations.
Resolving causative polymorphisms underlying QTL
Several features of our experimental system facilitated the
resolution of a likely causative sequence variant underlying a
mapped QTL. First, our study of a xenobiotic resistance trait
clearly motivated a focus on the small number of detoxifica-
tion family members within QTL. This ability to home in on
genes that were a priori highly likely to harbor segregating
causative variation may be unavailable for many other traits,
where the purpose of unbiased, genomewide mapping is to
help elucidate the pathways underlying variation. Second,
wewere fortunate that the causative gene possessed a variant
with a clear molecular signature of damage. The phenotypic
effects of most polymorphisms, particularly those associated
with noncoding changes, are considerably more challenging
to decipher from sequence data alone. Third, despite the QTL
containing multiple detoxification genes, and our prediction
that the QTL was generated by the action of multiple genes/
alleles (Marriage et al. 2014), the Ugt86Dd coding mutation
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alone has a major effect on phenotype that facilitated its de-
tection. Other study systems will lack these advantages. De-
spite these factors, all studies in Drosophila can leverage the
battery of functional tools available for this organism to drill
down to the causative molecular lesion(s) underlying QTL
and gain insight into the genetic control of trait variation.
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